Zurina Shamsuddin1*, Adibah Hanis Zainudin1, Jamiila Ismail1, Koay Bee Tee1, Salawati Mansor1, Asmadamia Abdul Aziz1, Masita Arip2, Norhazlin Mustafa1
1. Transplantation Immunology Unit, Allergy and Immunology Research Centre, Institute for Medical Research, National Institute of Health, Ministry of Health, 40170 Shah Alam, Selangor, Malaysia
2. Allergy and Immunology Research Centre, Institute for Medical Research, National Institute of Health, Ministry of Health, 40170 Shah Alam, Selangor, Malaysia
*Corresponding author: Zurina Shamsuddin.
ABSTRACT
INTRODUCTION: For patients suffering from end-stage renal disease (ESRD), renal transplantation is the best treatment option. Crossmatching testing methods, such as complement-dependent cytotoxicity (CDC) crossmatch and the Luminex single antigen bead (SAB) assay, are used to identify donor-specific antibodies (DSA) prior to organ transplants, which help to prevent antibody-mediated rejection. However, interpreting CDC positivity can be challenging, primarily in distinguishing clinically relevant IgG-mediated responses from the harmless IgM reactivity. The dithiothreitol (DTT) treatment helps differentiate between these antibody classes.
OBJECTIVE(S): This study evaluates the relationship between positive T-cell CDC crossmatch results and mean fluorescence intensity (MFI) values of Class I donor-specific HLA antibodies in kidney transplant candidates.
MATERIALS & METHODS: This is a retrospective analysis involving transplant candidates from various Malaysian hospitals with positive T-cell CDC crossmatch and their HLA antibody screening results. It includes 439 patient blood samples sent for CDC crossmatch tests from January 2023 to December 2024.
RESULTS: From the 439 samples, 19 (4.3%) were positive by CDC crossmatch. Following DTT treatment, 13 of these (68.4%) were determined to be IgM-mediated, while six (31.6%) were confirmed to be IgG-mediated. Among the six IgG-positive CDC crossmatches, five patients (83.3%) had detectable DSAs with a median MFI of 14,168 while one patient (16.7%) had no detectable DSA.
CONCLUSION: The majority of CDC crossmatch positivity in this cohort was attributable to IgM antibodies. Notably, nearly all IgG-mediated CDC crossmatch cases were associated with high-MFI DSAs, reinforcing the clinical relevance of combining CDC crossmatch with antibody profiling. A small subset of IgG-positive CDC results without detectable DSAs highlights the potential role of non-HLA antibodies or limitations in the current detection assays.
KEYWORDS: Renal Transplant, CDC Crossmatch, Donor-Specific Antibodies, Mean Fluorescence Intensity


